ÂÜÀòÂÒÂ×

I-Li Tan is a Senior Scientist at Evercrisp Biosciences since May 2023, with a rich background in cancer research. Previously, I-Li served as a Postdoctoral Researcher at Gladstone Institutes from January 2019 to April 2023, where work focused on utilizing CRISPR-Cas systems to investigate cancer dependencies and identify synthetic lethal targets for glioblastoma, along with developing in vivo delivery methods for therapeutic gene editing. I-Li's doctoral research at Weill Cornell Medical College (2012-2018) involved studying SHH-medulloblastoma tumorigenesis and therapeutic effects of CSF1R inhibition. Academic qualifications include a PhD in Cell and Developmental Biology from Weill Cornell and a BA in Cell/Cellular and Molecular Biology from the University of California, Berkeley.